ACC | Oncology Clinics and Infusion Center
15588
page-template-default,page,page-id-15588,page-child,parent-pageid-15216,ajax_fade,page_not_loaded,,qode-theme-ver-10.0,wpb-js-composer js-comp-ver-4.12,vc_responsive
 

Oncology Clinics and Infusion Center

About Naef K. Basile Cancer Institute – Ambulatory Treatment Unit and Clinics

Mission

The mission of the Naef K. Basile Cancer Institute (NKBCI) at the American University of Beirut Medical Center –Faculty of Medicine (AUBMC FM) is to reduce the burden of cancer in Lebanon and the region through the application of state-of-the-art medical knowledge and technology and the development of integrated and advanced programs in patient care, research, education and prevention.

 

Vision

The vision of the Naef K. Basile Cancer Institute (NKBCI) is to be a leading institute for cancer prevention and treatment through promoting excellence in patient care, research, and education and enhancing effectiveness and collaboration among cancer programs and healthcare providers.

 

History

The Naef K. Basile Cancer Institute (NKBCI) at the American University of Beirut Medical Center (AUBMC) became operational in 2007 upon receiving a generous contribution by the Naef K. Basile Foundation. The foundation was first established in 1995 following the death of Dr. Naef Basile, a Lebanese-American obstetrician-gynecologist whose lifelong wish was to give back to his country of birth through founding a cutting-edge cancer institute that would compare to the best cancer centers in the world.

 

Divisions

  1. Department of Radiation Therapy
  2. Division of Hematology Oncology
Faculty

Hassan El Solh, MD, FAAP, FRCP(C)

Director, the Naef K. Basile Cancer Institute

Medical Center Director and Chief Medical Officer
Director, Children’s Cancer Center Institute

Naef K. Basile Cancer Institute

Hs03@aub.edu.lb

Ext: 6003

 

Ali Shamseddine, MD, FRCP

Professor, Head of Hematology Oncology Division

Subspecialty: Gastro Intestinal and Genitourinary Oncology

As04@aub.edu.lb

Ext: 5150

 

Naji El Saghir, MD, FACP

Professor, Hematology Oncology

Director, Breast Center of Excellence

Subspecialty: Breast Cancer

Ns23@aub.edu.lb

Ext: 5150

 

Ali Taher, MD, PhD, FRCP

Professor, Hematology Oncology

Deputy Director – Naef K. Basile Cancer Institute

Subspecialty: Benign Hematology

ataher@aub.edu.lb

Ext: 5150

 

Hazem Assi, MD

Assistant Professor, Hematology Oncology

Subspecialty: Breast Cancer -Lung Cancer – Brain Tumors -Bone and Soft Tissue Sarcoma – Skin Cancer and Melanoma

Ha157@aub.edu.lb

Ext: 5150

 

Arafat Tfayli, MD

Professor, Hematology Oncology

Director of Fellowship Program

Subspecialty: Breast Cancer – Lung and Head and Neck Cancer

At35@aub.edu.lb

Ext: 5150

 

Deborah Mukherji, MD

Assistant Professor, Hematology Oncology

Subspecialty: Gastro Intestinal and Genitourinary Oncology

Dm25@aub.edu.lb

Ext: 5150

 

Sally Temraz, MD

Assistant Professor, Hematology Oncology

Subspecialty: Gastro Intestinal and Genitourinary Oncology

St29@aub.edu.lb

Ext: 5150

 

Jean El Cheikh, MD

Assistant Professor, Hematology Oncology

Subspecialty: Malignant Hematology / Stem Cells Transplant

Je46@aub.edu.lb

Ext: 5150

 

Ali Bazarbachi, MD, PhD

Professor, Hematology Oncology

Associate Dean for Basic Research

Director of Bone Marrow Transplant Unit

Subspecialty: Malignant Hematology / Stem Cells Transplant

bazarbac@aub.edu.lb

Ext: 5150

 

Fady Geara, MD, PhD

Professor, Chairperson of Radiation Oncology Department

Fg00@aub.edu.lb

Ext: 5198

 

Bassem Youssef, MD

Assistant Professor of Clinical Specialty

Specialty: Radiation Oncology

By04@aub.edu.lb

Ext: 5198

 

Toufic Eid, MD

Assistant Professor of Clinical Specialty

Specialty: Radiation Oncology

Te04@aub.edu.lb

Ext: 5198

 

Youssef Zeidan, MD

Assistant Professor of Clinical Specialty

Specialty: Radiation Oncology

Yz09@aub.edu.lb

Ext: 5198

Staff

Mira Wehbe Hariri, MPH

Clinical Department Administrator

Naef K. Basile Cancer Institute

Mw13@aub.edu.lb

Ext: 7903

 

Sana Murad, BSc

Secretary

Hematology Oncology Division

Sm137@aub.edu.lb

Ext: 5150

 

Joelle Basila, RN

Palliative Care Nurse

Naef K. Basile Cancer Institute

Jb32@aub.edu.lb

Ext: 7802

 

Jeanine Dede, BSc

Social Worker

Naef K. Basile Cancer Institute

Jd37@aub.edu.lb

Ext: 7843

 

Monita Darazi, RN, MSN

Clinical Trials Coordinator

Naef K. Basile Cancer Institute

Md99@aub.edu.lb

Ext: 7804

 

Rachelle Bejjani, RN, MPH

Clinical Trials Coordinator

Naef K. Basile Cancer Institute

Rb62@aub.edu.lb

Ext: 7803

 

Maya Charafeddine, MPH

Clinical Data Manager

Naef K. Basile Cancer Institute

Mc16@aub.edu.lb

Ext: 5110

 

Gladys Waked, BSc

Tumor Registry Assistant

Naef K. Basile Cancer Institute

Gw03@aub.edu.lb

Ext: 5111

 

Lina Arnaout, RN

Database Registrar

Naef K. Basile Cancer Institute

La11@aub.edu.lb

Ext: 5596

 

10 Research Fellows

Medical Doctors – MD

Naef K. Basile Cancer Institute

Ext: 7902

 

Chirine Chehab Akkawi, MPH

Clinical Department Administrator

Radiation Oncology Department

Cc07@aub.edu.lb

Ext: 5036

 

Mariam El Sabee, RN, BSN, MSNc

Registered Nurse, NKBCI Quality Officer

Naef K. Basile Cancer Institute

Ma240@aub.edu.lb

Ext: 8179

 

Zeinab Chahine, BSc

Coordinator – Breast Cancer Community Program

Naef K. Basile Cancer Institute

Zc08@aub.edu.lb

Ext: 8179

 

Residents & Fellows

Raafat Alameddine, MD

Hematology Oncology Division

3rd Year Fellow

Ra167@aub.edu.lb

​Pager: 0204

 

Iman Abou Dalle, MD

Hematology Oncology Division

3rd Year Fellow

Ia41@aub.edu.lb

​Pager: 0243

 

Amanda Chidiac, MD

Hematology Oncology Division

2nd Year Fellow

Ac32@aub.edu.lb

​Pager: 0161

 

Rana Salem, MD

Hematology Oncology Division

2nd Year Fellow

Rs170@aub.edu.lb

Pager: 0167

 

Haidar El Darsa, MD

Hematology Oncology Division

1st Year Fellow

He53@aub.edu.lb

​Pager: 0327

 

Nour Moukalled, MD

Hematology Oncology Division

1st Year Fellow

Nm90@aub.edu.lb

​Pager: 0309

  

Ibrahim Abu Gheida, MD

4th Year Resident

Radiation Oncology

Ia47@aub.edu.lb

​Pager: 1114

 

Karine Al Feghali, MD

4th Year Resident

Radiation Oncology

ka39@aub.edu.lb

​Pager: 1232

 

Lara Hilal, MD​

2nd Year Resident

​Radiation Oncology

lh54@aub.edu.lb

​Pager: 0213

 

Paul Ramia, MD​

1st Year Resident

​Radiation Oncology

pr04@aub.edu.lb

​Pager: 1105

 

Alexander Osman

1st Year Resident

Medical Physics in Radiation Oncology

ao13@aub.edu.lb

Ext: 5084

Community Outreach

The Naef K. Basile Cancer Institute has initiated community outreach activities in January 2016 upon the establishment of the Cancer Prevention and Control Program. This program aims at helping the community prevent cancer and decrease the burden of this disease through awareness, education, screening, counseling and research. The program includes a multidisciplinary team of clinicians and researchers, working in collaboration and coordination with community and health related organizations, leaderships of governments, policy-makers and others. Since January, several outreach activities have been conducted across Lebanon including Cancer Prevention Month at AUB, AUB Wellness Fair, lectures in Baakline, Byblos, Saida, Hasbaya, and Rashaya. A four -day awareness campaign was held in August 2016 at ABC Mall, Ashrafieh to raise awareness on cancer prevention and importance of early detection. Other awareness events will take place across the year in different areas in Lebanon and for different age group populations.

Patient Care

Our Services

NKBCI facilities have been originally set up to contain a spacious patient and family area that allows a friendly environment. Our commitment to patients goes beyond the delivery of sophisticated care; we respect the individual needs of all those who seek our care and we aim to empower patients with the knowledge and support they need to successfully fight cancer.

The Naef K. Basile Cancer Institute (NKBCI) at AUBMC serves as the Adult Hematology Oncology and Radiation Therapy Unit. NKBCI provides consultation services and care to patients with Solid Tumor and Hematological Malignancies in Lebanon and the region.

 

The Naef K. Basile Cancer Institute (NKBCI) consists of 4 major service units:

  1. Ambulatory Treatment Unit (Outpatient)
  2. Inpatient Unit
  3. Stem Cell Transplant Unit
  4. Radiotherapy Unit

 

Our services include the Oncology Program, Bone Marrow and Stem Cell Transplantation (Autologous and Allogeneic) Program, Research and Data Management, Educational Programs, Social Work Activities, Outreach Programs, and International Affiliations. Through its multidisciplinary team of physicians, nurses, administration and researchers, NKBCI attracts patients from Lebanon and the region who are seeking comprehensive care.

Divisions & Services

Hematology Oncology:

  • Ambulatory Treatment Unit (ATU)

The outpatient facility, located on the ground and second floors in Building 56 at AUBMC, can accommodate up to 29 outpatients concurrently allowing for significant increase in services in extended hours. Patients are admitted to the outpatient facility for chemotherapy, physical examinations, procedures, IV antibiotics, blood transfusions, and blood studies. Procedures such as bone marrow aspirates and biopsies are performed in the outpatient unit under conscious sedation. Moreover, patients are prepared in the outpatient area and referred for radiotherapy or for sophisticated laboratory and other studies such as MRI that require central device access and general anesthesia. The average number of patients visiting the Ambulatory Treatment Unit per day is 60 – 65 patients.

 

  • Inpatient Unit (IU)

The NKBCI inpatient facility is a multidisciplinary care unit located on the eighth floor of AUBMC, and it includes 32 patient beds. Patients are admitted to the inpatient facility for chemotherapy, procedures, investigation and management, as well as the treatment of underlying complications.

The average number of patients admitted in the inpatient unit per month is 228 with an average length of stay of 2.5 days.

 

  • Stem Cell Transplant Unit (SCT)

The NKBCI BMT Unit is located on the eighth floor of AUBMC and includes 8 positive pressures and High-Efficiency Particulate Air (HEPA) filtered rooms. Patients are admitted to the BMT Unit for stem cells transplantation, stem cells collection, and treatment of underlying complications post a transplant.

Providing the highest quality care standards, we have been able to cover for a continuously increasing number of stem cells transplants that has been observed across the past few years with the successful completion of 90 transplants in 2014 and 102 transplants in 2015.

 

Radiation Oncology (RO)

The Radiotherapy Unit is located on the basement floor of AUBMC. It includes four examination rooms, two treatment areas, one simulation room, a dosimetry lab, a brachytherapy room, and one laboratory. It uses state-of-the-art equipment to provide treatment for an average of 600 patients per year. The unit is actively involved in multi-disciplinary cancer management and high-dose rate brachytherapy, Intensity Modulated Radiotherapy (IMRT), Image Guided Radiotherapy (IGRT), Stereotactic Radiosurgery (SRS), and Fractionated Stereotactic Radiotherapy (SRT). With all these services, the unit currently provides patients with improved results and reduced side effects.

 

 

At what age do you start taking patients?

The Naef K. Basile Cancer Institute is a specialized cancer center for adults above 15 years of age. Only patients with specific blood disorders such as thalassemia and sickle cell anemia can be seen by our specialists below the age of 15.

How can I take an appointment in the hematology oncology clinic?

Please use the following numbers to schedule your appointment with our specialized hematology oncology doctors.

 

Phone Number: 00961 – 1 – 374 374 ext.: 7980

Direct Line: 00961 – 1 – 759 618

Fax: 00961 – 1 – 350 000 ext.: 7942

We promise to give you an appointment within maximum a week.

How can I take appointment in the radiation oncology clinic?

Please use the following numbers to schedule your appointment with our radiation oncologists.

 

Phone Number: 00961 – 1 – 374 374 ext.:5090/1

Direct Line: 00961 – 1 – 344 839

Fax: 00961 – 1 – 370 795

 

We promise to give you an appointment within maximum a week.

 

Do you support patients financially?

All patients presenting to AUBMC can request the support of the Social Services Department which serves as a link between the patient, community organizations, and other AUBMC staff. The Social Services Department is comprised of eligible individuals specialized in assisting patients with a range of social, emotional, family, and health related problems

Concerning Breast Cancer, a fund was established to support patients with the medical expenses on an Out-patient and In-patient basis (Therapeutic and Diagnostic) after being assessed by the Department of Social Services.

All other types of cancers are referred to the Department of Social Services for evaluation and assistance.

 

Can we donate hair?

We welcome your hair donations to support adult cancer patients who lost their hair due to treatment. If interested please contact:

Ms. Zeinab Chahine

Phone: 00961-1-350000 ext.: 8179

Email: zc08@aub.edu.lb

 

Can we donate money?

We welcome your financial donations to support all needy adult cancer patients. If interested please contact:

Ms. Mira Wehbe Hariri

Phone: 00961-1-350000 ext.: 7903

Email: mw13@aub.edu.lb

Research

Publications

NKBCI physicians are active researchers with more than 75 publications annually in prestigious international journals.

Below are a select of 2015 publications:

  1. Youssef B, Shank J, Reddy J, Pinnix C, Farha G, Akhtari M, Allen P, Fanale M, Garcia J, Horace T, Milgrom S, Smith G, Nieto Y, Arzu I, Wang H, Fowler N, Rodriguez M, Dabaja B. Radiation Oncology 2015. Incidence and Predictors of Lhermitte’s Sign among Patients Receiving Mediastinal Radiation for Lymphoma
  2. Zeidan YH, Geara F. Lebanon: an evolving hub for radiation therapy in the arab world. Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):888-91.
  3. Morris CR, Kim HY, Klings ES, Wood J, Porter JB, Trachtenberg F, Sweeters N, Olivieri NF, Kwiatkowski JL, Virzi L, Hassell K, Taher A, Neufeld EJ, Thompson AA, Larkin S, Suh JH, Vichinsky EP, Kuypers FA. Thalassemia Clinical Research Network. Dysregulated arginine metabolism and cardiopulmonary dysfunction in patients with thalassaemia. Br J Haematol. 2015 Jun;169(6):887-98. doi: 10.1111/bjh.13452. Epub 2015 Apr 24.
  4. Saliba AN, Taher AT. Comment on “Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multi-center randomized clinical trial”. Am J Hematol. 2015 Jun 4. doi: 10.1002/ajh.24080.
  5. Taher AT, Musallam KM, Saliba AN, Garziadei G, Cappellini MD. Hemoglobin level and morbidity in non-transfusion-dependent thalassemia. Blood Cells Mol Dis. 2015 Aug;55(2):108-9. doi: 10.1016/j.bcmd.2015.05.011. Epub 2015 May 30.
  6. Antar A, Kharfan-Dabaja MA, Mahfouz R, Bazarbachi A. Sorafenib Maintenance Appears Safe and Improves Clinical Outcomes in FLT3-ITD Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2015 May;15(5):298-302. doi:10.1016/j.clml. 2014.12.005. Epub 2014 Dec 12.
  7. Kharfan-Dabaja MA, Labopin M, Bazarbachi A, Socie G, Kroeger N, Blaise D, Veelken H, Bermudez A, Or R, Lioure B, Beelen D, Fegueux N, Hamladji RM, Nagler A, Mohty M. Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Leuk Res. 2015 Apr 24. pii: S0145-2126(15)00120-4. doi:
  8. Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, Arat M, Bader P, Baron F, Bazarbachi A, Blaise D, Ciceri F, Corbacioglu S, Dalle JH, Duarte RF, Fukuda T, Huynh A, Masszi T, Michallet M, Nagler A, NiChonghaile M, Pagluica T, Peters C, Petersen FB, Richardson PG, Ruutu T, Savani BN, Wallhult E, Yakoub-Agha I, Carreras E. Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT).
  9. Bone Marrow Transplant. 2015 Mar 23. doi: 10.1038/bmt.2015.52. [Epub ahead of print]
  10. El Saghir NS, Zgheib NK, Assi HA, Khoury KE, Bidet Y, Jaber SM, Charara RN, Farhat RA, Kreidieh FY, Decousus S, Romero P, Nemer GM, Salem Z, Shamseddine A, Tfayli A, Abbas J, Jamali F, Seoud M, Armstrong DK, Bignon YJ, Uhrhammer N. BRCA1 and BRCA2 Mutations in Ethnic Lebanese Arab Women With High Hereditary Risk Breast Cancer. Oncologist. 2015 Apr;20(4):357-64. doi: 10.1634/theoncologist.2014-0364. Epub 2015 Mar 16
  11. Hilal L, Shahait M, Mukherji D, Charafeddine M, Farhat Z, Temraz S, Khauli R, Shamseddine A. Prostate Cancer In The Arab World: A View From The Inside. Clinical Genitourinary Cancer. 2015
  12. Temraz S, Mukherji D, Shamseddine A. Dual Inhibition Of Mek And Pi3k Pathway In Kras And Braf Mutated Colorectal Cancers. International Journal Of Molecular Sciences. 2015, vol.16, no.9, pp-22976-88
  13. El-Cheikh J, Crocchiolo R, Furst S, Bramanti S, Sarina B, Granata A et al. Unrelated cord blood compared with haploidentical grafts in patients with hematological malignancies. Cancer 2015.
  14. El-Cheikh J, Crocchiolo R, Vai A, Furst S, Bramanti S, Sarina B, et al. Comparison of Three Distinct Prophylactic Agents Against Invasive Fungal Infections in Patients Undergoing Haplo-identical Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide. Mediterr J Hematol Infect Dis. 2015
  15. Assi H, Sbaity E, Abdel Salam M, Shamseddine A. Controversial Indications for Sentinel Lymph Node Biopsy in Breast Cancer Patients. BioMed Research International Volume 2015 (2015), Article ID 405949
  16. Khaled H, Azim HA, Barsoum E, Chahine G, Shamseddine A, Metaal GA, Omar A, Jazeih AR, Haggag R, Badran A. A multicenter, phase II study of the RAF-kinase inhibitor sorafenib in patients with advanced renal cell carcinoma. Mol Clin Oncol. 2015 Sep;3(5):1099-1102.
  17. Rafei H, Jabak S, Mina A, Tfayli A*. Pleurodesis In Malignant Pleural Effusions: Outcome And Predictors Of Success. Integrative Cancer Science And Therapeutics. 2015, vol.2, no.5, pp-216-221
  18. Mina A, Rafei H, Khalil M, Hassoun Y, Nasser Z, Tfayli A*Role Of Baseline Echocardiography Prior To Initiation Of Anthracycline-Based Chemotherapy In Breast Cancer Patients. Bmc Cancer. 2015, vol.15, no.1, pp-10
  19. Faraj W, El-Kehdy J, Nounou GE, Deeba S, Fakih H, Jabbour M, Haydar A, El Naaj AA, Abou-Alfa GK, O’Reilly EM, Shamseddine A, Khalife M, Mukherji D. Liver Resection For Metastatic Colorectal Leiomyosarcoma: A Single Center Experience.
    Journal Of Gastrointestinal Oncology. 2015, vol.6, no.5, pp-E70-6
  20. Assi R, Hamieh L, Mukherji D, Haydar A, Temraz T, El-Dika I, Shamseddine A. Leptomeningeal Metastasis as Initial Manifestation of Signet Ring Colorectal Adenocarcinoma: a Case Report with Review of Literature. J Gastrointest Oncol. 2015 Dec;6(6):E89-E101.

 

Ongoing Clinical Trials

Bazarbachi, Al

  • The Mechanism of Action of Arsenic Trioxide and Interferon Alpha in HTLV-I Associated Adult T-Cell Leukemia/Lymphoma (ATL)”
  • Phase I:Worldwide, Observational Registry Collecting Longitudinal Data On The Management Of Chronic Myelogenous Leukemia(Cml)Subjects(The World Cml Registry)In Routine Practice
  • Randomized, Double-Blind, Placebo Controlled, Multi -center Study Of Rad001 Adjuvant Therapy In Poor Risk Subjects With Diffuse Large B-Cell Lymphoma (Dlbcl) Of Rad001 Vs Matching Placebo After Subjects Have Achieved Complete Response
  • APL Model For Oncogene-Targeted Leukemia Cure
  • A Nationwide, Non-interventional, Epidemiological Data Registry On Myelodysplasia Syndromes In Lebanon
  • The Role of genetic Polymorphisms of Drug Metabolizing Enzymes and Transporters in the Interaction between Voriconazole & Cyclosporine in Patients undergoing Allogeneic Stem cell Transplantation: A Pilot Study

 

Geara, Fady

  • Randomized, Prospective, Open Label PHASE III trial Comparing MEBO Ointment with Biafine Cream for the Management of Acute Skin Reaction Caused by Postoperative Radiotherapy for Breast

 

Saghir, Nagi

  • Brca1 And Brca2 Mutations in Ethnic Lebanese Arab Women With Breast Cancer
  • Outcome of Subjects With Breast Cancer Treated Outside of Clinical Trials 2008-2010
  • Outcome of Patients With Early And Locally Advanced Breast Cancer Treated Outside Clinical Trials-Direg_L_04779 Study Extension
  • A Three-Arm Randomized, Open Label, Phase 2 Study of Everolimus In Combination With Exemestane Vs. Everolimus Alone Vs Capecitabine In The Treatment of Postmenauposal Women With Estrogen Receptor +, Locally Advanced Recurrent Or Metastatic Breast Cancer
  • A Multicenter Open-Label, Single Arm Study of Pertuzumab In Combination With Tstuzumab And A Taxane in First Line Treatment of Patients Advanced ( Metastatic Or Locally Advanced) Breast Cancer
  • Randomized, Double Blind, Placebo Controlled Study of Lee01 Or Placebo In Combination With Tamoxifen &Goserelin Or A Non -steroidal Aromatase Inhibtor & Goserlin For The Treatment of Pre-monopausal Women
  • A Randomized Double Blind Placebo Controlled Study of Ribociclib with Fulvestrant for the Treatment of Postmenopausal Women with Hormone Receptor Positive,HER-2Negative Advanced Breast Cancer Who Have Received No or Only 1 Line of Prior Endocrine Treatment

 

Shamseddine, Ali

  • Prognostic Determinants Of Outcome At Presentation in Young Lebanese Female Subjects <40 Years Compared to Those >40 Years With Newly Diagnosed Breast Carcinomas: A Prospective Clinicopathologic And Molecular Study
  • Carbazitaxel Cohort Compassionate Use Program In Subjects With Metastatic Hormone Refractory Prostate Cancer Previously Treated With Docetaxel Containing Regimen
  • A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
  • A Randomized, Double Blind, Multicenter, Phase I Study Of Everolimus (Rad001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in The Treatment of Patients With Advanced Net Of Gi Or Lung Origin

 

Taher, Ali

  • Prospective Comparison of Methods For Thrombolombolic Risk Assessment With Clinical Perceptions And Awareness in Real Life Cancer Subjects COMPASS-Cancer Study
  • A Single Arm, Multicenter, Phase ii Study to Explore The Efficacy &Safety Of Ruxolitinib (Inc424)In Regularly Transfused Patients With Thalassemia Truth
  • Myeloproliferative Neoplasms Epidemiological Registry in Growing And Emerging Markets – The Merge Study
  • An Open Label Multicenter Phase 4 Roll Over Protocol for Patients who Completed a Prior Global NOVARTIS or Incyte Sponsored Ruxolitinib (INC424) Study and are judged by the PI to Benefit From Continued Treatment

 

Tfayli, Arafat

  • Screening For The Prevalence of Egfr And Alk Mutations in Lung Adenocarcinoma Patients in The Levant Area, A Prospective Analysis
  • A Phase II, Multicenter,Three-Cohort Study of Oral cMET Inhibitor INC280 in Adult Patients with EGFR Wild-Type(wt), Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Received One or Two Prior Lines of Systemic Therapy
  • RIFTOS MKI-Radioactive Iodine Refractory Asymptomatic Patients in Differentiated Thyroid Cancer- An Observational Study to Assess the use of Multikinase Inhibitors
Education

The main objective behind the 4-year residency program at the Department of Radiation Oncology and the 3-year fellowship program at the Division of Hematology Oncology-Department of Internal Medicine at AUBMC is to train specialists serve in the region and identify unique individuals with outstanding research potential for further training in the United States. NKBCI physicians are involved in training residents and fellows in both the Inpatient (including SCT Unit) and Outpatient Units.

Alumni

Haifaa Dbouk, MD

Program: Fellowship

Hematology Oncology

Graduation Year: 2013

Current Hematologist Oncologist

Tyr, Lebanon

 

Hassan Farran, MD

Program: Fellowship

Hematology Oncology

Graduation Year: 2013

Curent Hematologist Oncologist

Saida, Lebanon

 

Ahmad Antar, MD

Program: Fellowship

Hematology Oncology

Graduation Year: 2014

Current Hematologist Oncologist

Al Moussa Center, Kingdom Of Saudi Arabia

 

David Wehbe, MD

Program: Fellowship

Hematology Oncology

Graduation Year: 2014

Current Hematologist Oncologist

Al Koura, Lebanon

 

Ibrahim Kaouk, MD

Program: Residency

Radiation Oncology

Preparing for STEP exams

Graduation Year: 2015

 

Hiba Moukaddem, MD

Program: Fellowship

Hematology Oncology

Graduation Year: 2015

Current Hematologist Oncologist

Beirut, Lebanon

 

Rita Assi, MD

Program: Fellowship

Hematology Oncology

Graduation Year: 2016

Advanced Oncology Fellowship Program

MDACC, Texas – Houston, USA

 

Imane El Dika, MD

Hematology Oncology

Graduation Year: 2016

Advanced Oncology Fellowship Program

MSKCC, New York, USA

 

Zeina Ayoub, MD

Program: Residency

Graduation Year: 2016

Advanced Oncology Fellowship Program

MDACC, Texas – Houston, USA

 

The ACC will feature an expansion of the chemotherapy ambulatory treatment unit to include 42 beds. This expansion will allow the accommodation of more patients in a timely and effective manner. With more subspecialized faculty joining the Naef K. Basile Cancer Institute at AUBMC, the number of clinics will increase to accommodate 5 physicians at the same time (with 2 clinics assigned to each physician) in addition to a clinic for fellows and clinical associates to examine drop in unscheduled cases. The flow of patients at the ACC will be based on patient centered care where the patient will be assessed by all concerned health professionals while staying in the same clinic without having to go from one room to another on the floor. A centralized phlebotomy lab and oncology pharmacy dedicated for our patients is another service of excellence provided at ACC.